Loading
NASDAQHealthcareBiotechnology
Latest quote
$31.00
+$0.92 · +3.06%
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Latest quote
$31.00
+$0.92 · +3.06%
After-hours
$31.00
$0.00 · 0.00%
Oct 9, 4:21 PM ET
Regular session · ET · Market data may be delayed.
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Day range
Current $31.00
52-week range
Current $31.00
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
37
Expensive
Sentiment
65
Bullish
Risk
27
Moderate Risk
Momentum
61
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Day range
Current $31.00
52-week range
Current $31.00
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 4.62M USD | — | — | — | — |
| Gross profit | −4.62M USD | — | — | — | — |
| Research and development | 269.78M USD | 232.66M USD | 173.76M USD | 121.63M USD | 55.91M USD |
| Selling, general, and administrative | 63.58M USD | 43.28M USD | 34.38M USD | 26.21M USD | 19.64M USD |
| Operating expenses | 328.74M USD | 275.94M USD | 208.13M USD | 147.84M USD | 75.55M USD |
| Interest income | 14.69M USD | 18.09M USD | 13.08M USD | 3.99M USD | 467K USD |
| Interest expense | 3.06M USD | — | — | 3.99M USD | — |
| Depreciation and amortization | 4.58M USD | 4.35M USD | 3.59M USD | 5.88M USD | 147K USD |
| Operating income | −333.36M USD | −275.94M USD | −208.13M USD | −147.84M USD | −75.55M USD |
| Net income | −328.94M USD | −255.86M USD | −192.41M USD | −140.24M USD | −72.27M USD |
Company facts updated Oct 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI180.91M0.01%2.3T USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM132.02M0.17%77.7B USD0.19%$278.93+0.49%
Vanguard Morningstar Small-Cap ETFVB130.8M0.07%185.3B USD0.03%$289.48+0.64%
State Street SPDR S&P Biotech ETFXBI121.73M1.20%10.11B USD0.35%$153.75+2.99%
Vanguard Morningstar Small-Cap Value ETFVBR83.02M0.12%68.2B USD0.05%$234.43+0.22%
Vanguard Extended Market ETFVXF69.5M0.07%95.4B USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO46.33M0.34%14.04B USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB36.27M0.34%10.41B USD0.44%$206.49+3.00%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Value ETFVBRVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.